Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1862098
                    [Title] => Dengvaxia seen to get EU accreditation
                    [Summary] => Despite the controversy in the Philippines, Dengvaxia has moved a step closer to becoming the first accredited vaccine against dengue in the European Union (EU).
                    [DatePublished] => 2018-10-22 00:00:00
                    [ColumnID] => 0
                    [Focus] => 1
                    [AuthorID] => 1804761
                    [AuthorName] => Helen Flores
                    [SectionName] => Headlines
                    [SectionUrl] => headlines
                    [URL] => http://media.philstar.com/images/articles/gen4-dengvaxia-box-ap_2018-10-21_22-21-29277_thumbnail.jpg
                )

            [1] => Array
                (
                    [ArticleID] => 1368187
                    [Title] => AstraZeneca launches breakthrough medication
                    [Summary] => 
Recognizing the difficulties being experienced by adult patients with Type 2 diabetes, pharmaceutical company, AstraZeneca, has developed a new oral medication that will aid Filipinos with Diabetes manage their situation better.

                    [DatePublished] => 2014-09-12 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Freeman Cebu Business
                    [SectionUrl] => cebu-business
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 916465
                    [Title] => US panel sees risk in long-used osteoporosis drug
                    [Summary] => 
A panel of U.S. government health experts says a long-established bone strengthening drug should no longer be used by women because there is little evidence it works and it may actually increase the risk of cancer.

                    [DatePublished] => 2013-03-06 10:40:17
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 913932
                    [Title] => Arnold, Mike for affordable health care
                    [Summary] => 
Kapuso Network’s Arnold Clavio and Mike Enriquez join RiteMed in its Right to Health campaign to promote access to world-class pharmaceutical and health care products at an affordable cost.

                    [DatePublished] => 2013-02-28 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Entertainment
                    [SectionUrl] => entertainment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 833899
                    [Title] => Novartis cancer drug gets Phl FDA approval
                    [Summary] => 
The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
                    [DatePublished] => 2012-08-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 830068
                    [Title] => European regulator: Gene therapy treatment OK
                    [Summary] => 
The European Medicines Agency is recommending the  first-ever approval of a gene therapy treatment in the EU, in a  significant move for a type of treatment that has so far failed to  deliver on its promise to cure diseases.
                    [DatePublished] => 2012-07-21 07:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 755739
                    [Title] => Implications of biosimilars in clinical practice tackled
                    [Summary] => 
Pharmaceutical company Roche recently conducted a medical symposium where it invited doctors from various specialties such as medical oncology, rheumatology, endocrinology, gastroenterology, and nephrology for a scientific meeting about the opportunities and challenges of biotherapeutics in clinical practices.
                    [DatePublished] => 2011-12-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 746003
                    [Title] => SmokeLess passes strict European standards on organic drugs
                    [Summary] => 
While most herbal drugs maintain its label of “no therapeutic claims,” Neuravena, the main, active ingredient of SmokeLess, however, has been given a seal of approval from the European Medicines Agency (EMA), a decentralized body of the European Union that is regarded as having one of the most stringent and highest-quality standards among developed countries.
                    [DatePublished] => 2011-11-10 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 653470
                    [Title] => Early success of Roche drug vs lung cancer cited
                    [Summary] => SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.
                    [DatePublished] => 2011-02-03 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [9] => Array
                (
                    [ArticleID] => 632713
                    [Title] => Roche gets license for EGFR lung cancer assay
                    [Summary] => 
Roche announced recently that it has obtained a worldwide sub-license from Genzyme Corp. to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.
                    [DatePublished] => 2010-11-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

European Medicines Agency

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1862098
                    [Title] => Dengvaxia seen to get EU accreditation
                    [Summary] => Despite the controversy in the Philippines, Dengvaxia has moved a step closer to becoming the first accredited vaccine against dengue in the European Union (EU).
                    [DatePublished] => 2018-10-22 00:00:00
                    [ColumnID] => 0
                    [Focus] => 1
                    [AuthorID] => 1804761
                    [AuthorName] => Helen Flores
                    [SectionName] => Headlines
                    [SectionUrl] => headlines
                    [URL] => http://media.philstar.com/images/articles/gen4-dengvaxia-box-ap_2018-10-21_22-21-29277_thumbnail.jpg
                )

            [1] => Array
                (
                    [ArticleID] => 1368187
                    [Title] => AstraZeneca launches breakthrough medication
                    [Summary] => 
Recognizing the difficulties being experienced by adult patients with Type 2 diabetes, pharmaceutical company, AstraZeneca, has developed a new oral medication that will aid Filipinos with Diabetes manage their situation better.

                    [DatePublished] => 2014-09-12 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Freeman Cebu Business
                    [SectionUrl] => cebu-business
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 916465
                    [Title] => US panel sees risk in long-used osteoporosis drug
                    [Summary] => 
A panel of U.S. government health experts says a long-established bone strengthening drug should no longer be used by women because there is little evidence it works and it may actually increase the risk of cancer.

                    [DatePublished] => 2013-03-06 10:40:17
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 913932
                    [Title] => Arnold, Mike for affordable health care
                    [Summary] => 
Kapuso Network’s Arnold Clavio and Mike Enriquez join RiteMed in its Right to Health campaign to promote access to world-class pharmaceutical and health care products at an affordable cost.

                    [DatePublished] => 2013-02-28 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Entertainment
                    [SectionUrl] => entertainment
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 833899
                    [Title] => Novartis cancer drug gets Phl FDA approval
                    [Summary] => 
The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
                    [DatePublished] => 2012-08-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 830068
                    [Title] => European regulator: Gene therapy treatment OK
                    [Summary] => 
The European Medicines Agency is recommending the  first-ever approval of a gene therapy treatment in the EU, in a  significant move for a type of treatment that has so far failed to  deliver on its promise to cure diseases.
                    [DatePublished] => 2012-07-21 07:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 755739
                    [Title] => Implications of biosimilars in clinical practice tackled
                    [Summary] => 
Pharmaceutical company Roche recently conducted a medical symposium where it invited doctors from various specialties such as medical oncology, rheumatology, endocrinology, gastroenterology, and nephrology for a scientific meeting about the opportunities and challenges of biotherapeutics in clinical practices.
                    [DatePublished] => 2011-12-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 746003
                    [Title] => SmokeLess passes strict European standards on organic drugs
                    [Summary] => 
While most herbal drugs maintain its label of “no therapeutic claims,” Neuravena, the main, active ingredient of SmokeLess, however, has been given a seal of approval from the European Medicines Agency (EMA), a decentralized body of the European Union that is regarded as having one of the most stringent and highest-quality standards among developed countries.
                    [DatePublished] => 2011-11-10 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 653470
                    [Title] => Early success of Roche drug vs lung cancer cited
                    [Summary] => SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.
                    [DatePublished] => 2011-02-03 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [9] => Array
                (
                    [ArticleID] => 632713
                    [Title] => Roche gets license for EGFR lung cancer assay
                    [Summary] => 
Roche announced recently that it has obtained a worldwide sub-license from Genzyme Corp. to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.
                    [DatePublished] => 2010-11-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Dengvaxia seen to get EU accreditation

By Helen Flores | October 22, 2018 - 12:00am

Despite the controversy in the Philippines, Dengvaxia has moved a step closer to becoming the first accredited vaccine against...

Headlines

AstraZeneca launches breakthrough medication

September 12, 2014 - 12:00am

Recognizing the difficulties being experienced by adult patients with Type 2 diabetes, pharmaceutical company, AstraZeneca, has developed a new oral medication that will aid Filipinos with Diabetes manage their situation...

Freeman Cebu Business

US panel sees risk in long-used osteoporosis drug

March 6, 2013 - 10:40am

A panel of U.S. government health experts says a long-established bone strengthening drug should no longer be used by women because there is little evidence it works and it may actually increase the risk of can...

Health And Family

Arnold, Mike for affordable health care

February 28, 2013 - 12:00am

Kapuso Network’s Arnold Clavio and Mike Enriquez join RiteMed in its Right to Health campaign to promote access to world-class pharmaceutical and health care products at an affordable cost.

Entertainment

Novartis cancer drug gets Phl FDA approval

August 2, 2012 - 12:00am

The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast...

Science and Environment

European regulator: Gene therapy treatment OK

July 21, 2012 - 7:00am

The European Medicines Agency is recommending the first-ever approval of a gene therapy treatment in the EU, in a significant move for a type of treatment that has so far failed to deliver on its promise to cure...

Implications of biosimilars in clinical practice tackled

December 8, 2011 - 12:00am

Pharmaceutical company Roche recently conducted a medical symposium where it invited doctors from various specialties such as medical oncology, rheumatology, endocrinology, gastroenterology, and nephrology for a...

Science and Environment

SmokeLess passes strict European standards on organic drugs

November 10, 2011 - 12:00am

While most herbal drugs maintain its label of “no therapeutic claims,” Neuravena, the main, active ingredient of SmokeLess, however, has been given a seal of approval from the European Medicines Agency...

Science and Environment

Early success of Roche drug vs lung cancer cited

February 3, 2011 - 12:00am

SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.

Science and Environment

Roche gets license for EGFR lung cancer assay

November 25, 2010 - 12:00am

Roche announced recently that it has obtained a worldwide sub-license from Genzyme Corp. to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.

Science and Environment